At a glance
ClinicalIndex Comparison RecordPhase 3Active· 299 enrolled
Drug / intervention
troriluzole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
In Brief
A Phase 3 clinical trial evaluating troriluzole and Placebo for Spinocerebellar Ataxias and 7 related conditions. Active but no longer recruiting, targeting 299 participants across 23 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
CountriesChina, United States
Collaborators--
Timeline
Phase 3Active
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartMar 2019
Primary CompletionFeb 2022
TodayJul 2026
Study CompletionAug 2026
First PostedOct 10, 2018
Enrollment StartMar 8, 2019
Primary CompletionFeb 18, 2022
Study CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.7 years ago
Interventions
troriluzoledrug
Administered orally
Placebodrug
Administered orally